申请人:GLAXOSMITHKLINE LLC
公开号:WO2011054773A1
公开(公告)日:2011-05-12
There are provided according to the invention novel compounds of formula (I) or a pharmaceutically acceptable salt thereof: wherein R is halogen, C1-4 alkyl or trifluoromethyl; R1, R2, R7, R8, R9, R10, R11 and R12 are independently hydrogen, halogen, C(O)NH2, C(O)NHC 1-6 alkyl, C(O)N(C 1-6 alkyl)2, C 3-8 cycloalkyl, haloC1-6 alkyl or C 1-6 alkyl optionally substituted by one or more hydroxyl groups, C 3-8 cycloalkyl or C 1-6 alkoxy; R3 is hydrogen, C 1-6 alkyl or haloC 1-6 alkyl; R4 and R5 are independently hydrogen or C 1-4 alkyl; R6 is trifluoromethyl, halogen, trifluoromethoxy, C 1-6 alkoxy or C 1-4 alkyl; m is an integer from 0 to 2; q is 1 or 2; n is 1 and p is 0 or n is 0 and p is 1.
根据本发明,提供了具有通式(I)的新化合物或其药学上可接受的盐:其中R为卤素、C1-4烷基或三氟甲基;R1、R2、R7、R8、R9、R10、R11和R12各自独立地为氢、卤素、C(O)NH2、C(O)NHC1-6烷基、C(O)N(C1-6烷基)2、C3-8环烷基、卤代C1-6烷基或C1-6烷基,后者可选择性地被一个或多个羟基、C3-8环烷基或C1-6烷氧基取代;R3为氢、C1-6烷基或卤代C1-6烷基;R4和R5各自独立地为氢或C1-4烷基;R6为三氟甲基、卤素、三氟甲氧基、C1-6烷氧基或C1-4烷基;m为0至2的整数;q为1或2;n为1且p为0,或者n为0且p为1。